My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about GENZ

    CAMBRIDGE, Mass., Oct. 20 /PRNewswire-FirstCall/ -- Genzyme Corporation
 (Nasdaq:   GENZ) announced today that scientists have again named the company
 a top employer in a survey ranking the reputations of biotechnology and
 pharmaceutical companies. Genzyme placed 6th among the 331 global companies
 included in the survey and is the highest ranked company in New England.
     The survey, which was commissioned by the journal, Science, and the
 American Association for the Advancement of Science, identifies the top 20
 companies with the best reputations as employers. More than 650 Science
 readers participated in the survey.
     "To be regarded consistently as one of the top life science employers
 is a great honor," said Alan Smith, Ph.D., Genzyme's chief scientific
 officer. "Genzyme has more products in development today than we've had at
 any other point in our history. This is due in very large part to the work
 of our exceptional scientists, and they will continue to play a key role in
 Genzyme's growth and sustainability in the future."
     The survey was conducted from May 2 to June 4, 2006. Science
 subscribers were invited to respond to the survey, and asked to submit the
 names of companies they considered the best, average and worst employers.
     The respondents then rated those companies on 42 different attributes
 from seven categories. The categories included corporate image, leadership
 and direction, financial prowess, work culture/environment, work/life
 balance, academics and collegial exchange, and compensation and benefits.
 More than 30 percent of the respondents came from outside the United
 States, primarily Western Europe.
     Genzyme's highest ratings included those for two attributes that
 respondents identified as being among the most important when evaluating an
 employer: having a clear vision for the future, and being an innovative
 leader in the industry. Genzyme received the 4th highest ranking for having
 a clear vision, and tied for 5th place for being an innovative leader.
     "We are pleased to know that our reputation among scientists is
 strong," said Zoltan Csimma, Genzyme's chief human resources officer. "At
 Genzyme, we place a high priority on attracting and retaining talented
 people in all areas of the company, because we believe that each individual
 has the power to make a difference."
     Scientists working at Genzyme are developing new and next-generation
 therapies in several areas of medicine using a wide range of technologies.
 The company is bringing new treatments to patients with genetic diseases,
 kidney disease, cancer, osteoarthritis, and transplant and immune diseases.
 The company is also a leader in the development of diagnostic and genetic
 tests.
     More than 1,800 people are employed in research and development
 positions at Genzyme. Genzyme's primary research and development facilities
 are in Massachusetts, where the company is currently expanding its
 presence. Genzyme is building a new, 177,000-square-foot facility in
 Framingham to house early stage scientific research and is expanding an
 existing polymer and small-molecule research facility in Waltham. Genzyme
 last year opened its first discovery research facility outside the United
 States in Cambridge, U.K.
     The survey results appear in a special supplement to the October 20
 issue of Science. To read the full survey, please visit:
 http://sciencecareers.sciencemag.org/career_development/more_topics/busines
 s_o ffice_supplements
     For information about other recognition Genzyme has received, please
 visit: http://www.genzyme.com/corp/structure/awards_genz.asp
     For information about careers at Genzyme, please visit:
 http://www.genzyme.com/careers
     About Genzyme
     One of the world's leading biotechnology companies, Genzyme is
 dedicated to making a major positive impact on the lives of people with
 serious diseases. This year marks the 25th anniversary of Genzyme's
 founding. Since 1981, the company has grown from a small start-up to a
 diversified enterprise with more than 8,500 employees in locations spanning
 the globe and 2005 revenues of $2.7 billion. Genzyme has been selected by
 FORTUNE as one of the "100 Best Companies to Work for" in the United
 States.
     With many established products and services helping patients in more
 than 80 countries, Genzyme is a leader in the effort to develop and apply
 the most advanced technologies in the life sciences. The company's products
 and services are focused on rare inherited disorders, kidney disease,
 orthopaedics, cancer, transplant and immune diseases, and diagnostic
 testing. Genzyme's commitment to innovation continues today with a
 substantial development program focused on these fields, as well as heart
 disease and other areas of unmet medical need.
     About AAAS
     The American Association for the Advancement of Science (AAAS) is the
 world's largest general scientific society, and publisher of the journal,
 Science (http://www.sciencemag.org). AAAS was founded in 1848, and includes
 some 262 affiliated societies and academies of science, serving 10 million
 individuals. Science has the largest paid circulation of any peer-reviewed
 general science journal in the world, with an estimated total readership of
 one million. The non-profit AAAS (http://www.aaas.org) is open to all and
 fulfills its mission to "advance science and serve society" through
 initiatives in science policy; international programs; science education;
 and more.
     Genzyme(R) is a registered trademark of Genzyme Corporation. All rights
 reserved.
     Genzyme's press releases and other company information are available at
 http://www.genzyme.com and by calling Genzyme's investor information line
 at 1-800-905-4369 within the United States or 1-703-797-1866 outside the
 United States.
     Media Contact:
     Erin Emlock
     (617) 768-6923
 
 

SOURCE Genzyme Corporation